PDCD1LG2 anticorps (PE)

N° du produit ABIN2663274

Détail du produit anti-PDCD1LG2 anticorps (PE)

Antigène: PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp PDCD1LG2 est conjugé à/à la PE

Application: ELISA (Detection)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: TY25

Isotype: IgG2a kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur PDCD1LG2

Antigène: PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))

Autre désignation: CD273 (PDCD1LG2 Produits)

Synonymes: anticorps PDL2, anticorps B7DC, anticorps Btdc, anticorps CD273, anticorps PD-L2, anticorps PDCD1L2, anticorps bA574F11.2, anticorps B7-DC, anticorps F730015O22Rik, anticorps programmed cell death 1 ligand 2, anticorps PDCD1LG2, anticorps Pdcd1lg2

Sujet: B7-DC is also called programmed death ligand 2 (PDL2). It has recently been clustered as CD273. This ligand is a 42 kD member of the immunoglobulin receptor superfamily expressed on a subset of dendritic cells, liver and a small subset of macrophages as well as a few transformed cell lines. CD273 has been reported to be stimulatory on dendritic cells when cross-linked and to inhibit T cell activation upon engaging the PD-1 receptor. CD273 has also been reported to bind to an alternative receptor and to mediate T cell activation through such non-PD1 mediated interactions. The TY25 antibody has been reported to be useful for blocking PD-1 mediated interactions.